Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 470,266 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 470,266 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the transaction, the insider directly owned 1,522,058 shares in the company, valued at $20,045,503.86. This trade represents a 23.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Adaptive Biotechnologies Trading Up 5.8%

Shares of ADPT stock opened at $13.17 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $6.68 and a 12-month high of $20.76. The business’s fifty day simple moving average is $16.55 and its 200-day simple moving average is $15.85. The company has a market cap of $2.03 billion, a PE ratio of -32.92 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same period in the previous year, the business posted ($0.23) EPS. The business’s revenue was up 51.0% compared to the same quarter last year. On average, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth $28,000. Sound Income Strategies LLC acquired a new stake in Adaptive Biotechnologies during the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC increased its position in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. increased its stake in shares of Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Adaptive Biotechnologies during the 4th quarter valued at about $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of research analyst reports. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research report on Friday, February 6th. BTIG Research upped their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Guggenheim raised their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Finally, Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.